Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva. The company said five presentations will showcase its current and future approaches to migraine prevention, including new analyses for eptinezumab and primary phase 2b PROCEED data for the investigational treatment bocunebart. Lundbeck said the […]
Helus Pharma, a clinical stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has appointed Jill Conwell as Chief People Officer, effective immediately
